Diagnosis and management of sudden cardiac death

Heart

Volumn 91, Issue 3, 2005, Pages 408-413

  Spector, Peter S ^a  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; AMIODARONE; ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENCAINIDE; FLECAINIDE; LOOP DIURETIC AGENT; MORACIZINE; PLACEBO; SOTALOL; TRANDOLAPRIL; CARDIOVASCULAR AGENT;

CARDIOMYOPATHY; CAUSE OF DEATH; DEFIBRILLATOR; DRUG EFFICACY; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART VENTRICLE FIBRILLATION; HUMAN; PRIORITY JOURNAL; REENTRY ARRHYTHMIA; REVIEW; RISK ASSESSMENT; SUDDEN DEATH; HEART ARRHYTHMIA; METHODOLOGY;

ARRHYTHMIA; CARDIOMYOPATHIES; CARDIOVASCULAR AGENTS; DEATH, SUDDEN, CARDIAC; DEFIBRILLATORS, IMPLANTABLE; HUMANS; MYOCARDIAL ISCHEMIA; RISK ASSESSMENT; VENTRICULAR FIBRILLATION;

EID: 14244266428     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.2003.024026     Document Type: Review

References (20)

1. Engdahl J, Holmberg M, Karlson BW, et al. The epidemiology of out-of-hospital 'sudden' cardiac arrest. Resuscitation 2002;52:235-45.
2. Banville I, Gray RA. Effect of action potential duration and conduction velocity restitution and their spatial dispersion on alternans and the stability of arrhythmias. J Cardiovasc Electrophysiol 2002;13:1141-9. An easy to understand summary of the restitution hypothesis.
3. Laurita KR, Girouard SD, Akar FG, et al. Modulated dispersion explains changes in arrhythmia vulnerability during premature stimulation of the heart. Circulation 1998;98:2774-80. A compelling set of experiments demonstrating the dynamic nature of action potential characteristics and VF vulnerability.
4. Garfinkel A, Kim YH, Voroshilovsky O, et al. Preventing ventricular fibrillation by flattening cardiac restitution. Proc Natl Acad Sci U S A 2000;97:6061-6. A well designed and provocative investigation of the antifibrillatory effects of flattening the slope of the restitution curve.
5. Janse MJ, Wit AL. Electrophysiological mechanisms of ventricular arrhythmias resulting from myocardial ischemia and infarction. Physiol Rev 1989;69:1049-169. An excellent review of the electrophysiological effects of ischaemia and infarction.
6. Pogwizd SM, Bers DM. Calcium cycling in heart failure: the arrhythmia connection. J Cardiovasc Electrophysiol 2002;13:88-91. A concise and coherent overview of the role of intracellular calcium handling in the electrophysiology of ventricular arrhythmias in heart failure.
7. Pogwizd SM, Schlotthauer K, Li L, et al. Arrhythmogenesis and contractile dysfunction in heart failure: roles of sodium-calcium exchange, inward rectifier potassium current, and residual beta-adrenergic responsiveness. Circ Res 2001;88:1159-67. An elegant examination of electrical remodelling in the rabbit model of heart failure.
8. Laurita KR, Rosenbaum DS. Interdependence of modulated dispersion and tissue structure in the mechanism of unidirectional block. Circ Res 2000;87:922-8. A beautiful demonstration of the interaction between functional and anatomic substrate in re-entrant arrhythmias.
9. Greene HL. The CASCADE study: randomized antiarrhythmic drug therapy in survivors of cardiac arrest in Seattle. CASCADE investigators. Am J Cardiol 1993;72:70F-4F.
10. Julian DG, Camm AJ, Frangin G, et al. Randomized trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. European myocardial infarct amiodarone trial investigators, Lancet 1997;349:667-74.
11. Cairns JA, Connolly SJ, Roberts R, et al. Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Canadian amiodarone myocardial infarction arrhythmia trial investigators. Lancet 1997;349:675-82.
12. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report effect of encainide ana flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989;321:406-12. An extremely important paper demonstrating that, despite reducing premature ventricular contractions, flecainide and encainide increased mortaliiy in past-Mi patients with ventricular ectopy.
13. Tan LB. SWORD trial of d-sotalol. Lancet 1996;348:827-8.
14. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med 1997;337:1576-83.
15. Connolly SJ, Gent M, Roberts RS, et al. Canadian implantable defibrillator study (CIDS): a randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation 2000;101:1297-302.
16. Kuck KH, Cappato R, Siebels J, et al. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: the cardiac arrest study Hamburg (CASH). Circulation 2000;102:748-54.
17. Moss AJ, Hall WJ, Cannom DS, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter automatic defibrillator implantation trial investigators. N Engl J Med 1996;335:1933-40. A comparison of ICD and "conventional treatment" for prevention of SCD. This trial resulted in a dramatic shift in ICD usage as primary prevention of SCD.
18. Lee KL, Hafley G, Fisher JD, et al. Effect of implantable defibrillators on arrhythmic events and mortality in the multicenter unsustained tachycardia trial. Circulation 2002;106:233-8.
19. Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002;346:877-83. An examination of ICDs for primary prevention of SCD in patients with ischaemic cardiomyopathy and no other risk factors. Like the MADIT I trial, MADIT II dramatically increased the indications for ICD implantation.
20. Coronary Artery Bypass Graft (CABG) Patch Trial Investigators. Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary-artery bypass graft surgery. N Engl J Med 1997;337:1569-75.